Breaks Categories: News

FridayAug 11, 2023 2:35 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the report also included a business update. Highlights of the report include R&D expenses for the quarter totaled $1.45 million compared with $1.97 million for the same period in 2022; marketing, general and administrative expenses for the quarter reached $1.14 million compared with $1.29 million for the 2022 period; total operating expenses for the quarter amounted to $2.56 million compared with…

Continue Reading

FridayAug 11, 2023 2:26 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Updated Information Regarding SRM Entertainment Spin-Off, Closes on Safety Shot Acquisition

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has released the updated payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. SRM Entertainment is currently a majority-owned subsidiary of Jupiter Wellness. According to the announcement, the date to effect the spin-off of the SRM business is planned for Aug. 14, 2023; the payment date remains subject to SRM’s Registration Statement on Form S-1 being declared effective by the U.S. Securities and Exchange Commission. “In the event that such registration statement is not declared effective…

Continue Reading

FridayAug 11, 2023 1:00 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 million registered direct offering, resulting in gross proceeds for HeartBeam of $26.5 million; the announcement in the “Journal of American College of Cardiology: Advances” of a foundational study evaluating the ability of the company’s VECG technology platform to detect the presence of coronary artery occlusions;…

Continue Reading

ThursdayAug 10, 2023 1:28 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to the company’s lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). In addition to ODD for the treatment of SCLC, in June 2023, the FDA granted Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy, in combination with Genentech Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression…

Continue Reading

WednesdayAug 09, 2023 12:48 pm

BioMedNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Deliver One-of-a-Kind Technology Across US Market

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, today announced its execution of an exclusive deal with Italian biomedical manufacturing company, BPB Medica. This comes as HippoFi’s PUR Biologics is preparing to launch PURmarrow360 throughout the U.S., aiming to provide a safe and simple surgical device, specifically designed to selectively capture a patient’s own bone marrow aspirate (“BMA”) and mesenchymal stem cells (“MSCs”). Surgeons can combine these patient-specific live-cells with any allograft, allogenic or synthetic bone substitute during surgery. “We are confident in the executive leadership and experience of HippoFi and PUR Biologics and…

Continue Reading

WednesdayAug 09, 2023 11:53 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Positive Efficacy Results from Clinical Study of NoStingz

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced data from a recent clinical study of NoStingz, its proprietary topical sunscreen formulated to protect users from jellyfish, sea lice and UVA/UVB rays. According to the update, Portuguese man-o’-war (“MOW”), a marine hydrozoan closely related to jellyfish, has a powerful sting that has been known to kill humans. The present study used MOW gathered from the Atlantic Ocean near Key West, Florida, in 51 trials conducted testing three sunscreen compounds, including NoStingz, against control. Reportedly, the NoStingz area of the participants’ arms had a statistically significant…

Continue Reading

WednesdayAug 09, 2023 11:44 am

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and GEDi Cube Intl Ltd. have executed a binding, exclusive letter of intent (“LOI”). The LOI outlines the merge of a subsidiary with GEDi Cube, a cutting-edge health AI company. According to the announcement, the resulting company would focus on accelerating the diagnosis of cancer and other diseases, as well as enhancing treatment effectiveness, discovering new therapies and expanding access to life-saving technologies. According to the announcement, Renovaro Biosciences officials…

Continue Reading

WednesdayAug 09, 2023 11:06 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces First Peer-Reviewed Publication Based on Its VECG Technology

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages. The publication* appeared in JACC: Advances, a journal of the American College of Cardiology, and discussed how HeartBeam’s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12-lead…

Continue Reading

TuesdayAug 08, 2023 1:01 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Deborah Castillo to Lead Regulatory Strategy and Execution

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced its appointment of Deborah Castillo, PhD, as vice president of regulatory affairs. An experienced biomedical engineer with extensive knowledge of FDA, EU and Health Canada regulations, Castillo has significant expertise in cardiovascular diseases, neuroscience and medical devices that support these functions. Prior to joining HeartBeam, Deborah served as director of regulatory affairs neuromodulation at LivaNova, a global medical device company creating…

Continue Reading

FridayAug 04, 2023 3:33 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “The FTD is for the company’s Acclaim-3 patient population, and Genprex expects to initiate its Acclaim-3 clinical trial by enrolling the first patient in the third quarter of 2023… The company previously received two other FTDs. In 2020, Genprex…

Continue Reading